HC Wainwright & Co. Maintains Buy on Vanda Pharmaceuticals, Lowers Price Target to $20
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsPrice Target
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Vanda Pharmaceuticals (NASDAQ:VNDA) with a Buy and lowers the price target from $21 to $20.
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Vanda Pharmaceuticals (NASDAQ:VNDA) with a Buy and lowers the price target from $21 to $20.